There is a need for new and effective antiretrovirals.

The purpose of this clinical trial is to study different doses of GW695634G, including how well each dose is tolerated as well as its safety and effectiveness.

This experimental drug has been designed to work against HIV that has become resistant to other NNRTI.

 

 

This new clinical trial is a randomized, placebo-controlled Phase I, double-blinded, 7-day study of an experimental NNRTI (GW695634G).

Study volunteers will be randomly assigned to one of five treatment groups. Four groups will receive the study drug in different doses, one group will receive placebo. Study volunteers must stop taking all anti-HIV medications one month prior to beginning this study. This study compensates up to $615 for your time and inconvenience.

This study also includes resistance testing via the VirtualPhenotype.

 

• HIV-positive adult
• Viral load greater than 2000
• T-cell count greater than or equal to 200
• Eligibility is based on past and current drug resistance testing to NNRTIs
• Must stop taking all anti-HIV medications one month prior to starting the study

Enrolling
--

This ad was reviewed and approved by the AIDS ReSearch Alliance Institutional Review Board in June, 2004.